Chinese scientists have conducted a search of randomized controlled study of the efficacy and safety of antiretroviral lopinavir/ritonavir and antiviral Arbidol (umifenovir) in patients with coronavirus infection. The results obtained showed that both drugs do not help improve the outcomes of patients, but there are side effects, according to the EurekAlert website.
As a combination of lopinavir/ritonavir and Arbidol, in a number of countries included in the lists of recommended drugs for the treatment of coronavirus infection on the basis of in vitro studies and experiences with outbreaks of SARS and MERS. Previously it was shown that lopinavir/ritonavir does not improve outcomes in patients with severe COVID-19, this study evaluated the effectiveness of the drug in patients with easy and moderate severity disease.
The study involved 86 patients, 34 of them were randomized to receive lopinavir/ritonavir 35 – Arbidol, 17 people were included in the control group and received only supportive therapy. It turned out that active therapy had no effect on the outcomes of patients after 7 and 14 days were also not revealed significant differences in terms of temperature, the severity of cough and CT. Also in the active treatment groups was observed the development of adverse events, including diarrhea, nausea, loss of appetite.